Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Vaccines

  Free Subscription


Articles published in Nat Med

Retrieve available abstracts of 118 articles:
HTML format



Single Articles


    July 2024
  1. XU H, Zou K, Dent J, Wiens KE, et al
    Author Correction: Enhanced cholera surveillance to improve vaccination campaign efficiency.
    Nat Med. 2024 Jul 9. doi: 10.1038/s41591-024-03176.
    PubMed    


    June 2024
  2. ZHONG Y, Kang AYH, Tay CJX, Li HE, et al
    Publisher Correction: Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children.
    Nat Med. 2024 Jun 10. doi: 10.1038/s41591-024-03107.
    PubMed    


  3. LAZARUS JV, White TM, Wyka K, Ratzan SC, et al
    Influence of COVID-19 on trust in routine immunization, health information sources and pandemic preparedness in 23 countries in 2023.
    Nat Med. 2024;30:1559-1563.
    PubMed     Abstract available


  4. CLIFF M, Welaga P, Mohammed N, Ansah P, et al
    Strategies for controlling pneumococcal disease and outbreaks during humanitarian emergencies.
    Nat Med. 2024;30:1515-1516.
    PubMed    


    May 2024
  5. MENTZER AJ, Dilthey AT, Pollard M, Gurdasani D, et al
    High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response.
    Nat Med. 2024 May 13. doi: 10.1038/s41591-024-02944.
    PubMed     Abstract available


    April 2024
  6. ZHONG Y, Kang AYH, Tay CJX, Li HE, et al
    Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children.
    Nat Med. 2024 Apr 30. doi: 10.1038/s41591-024-02962.
    PubMed     Abstract available


  7. SARAF A, Gurjar R, Kaviraj S, Kulkarni A, et al
    An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.
    Nat Med. 2024 Apr 18. doi: 10.1038/s41591-024-02955.
    PubMed     Abstract available


  8. ARNOLD C
    'Inverse vaccines' could treat autoimmune disease - from multiple sclerosis to celiac disease.
    Nat Med. 2024 Apr 10. doi: 10.1038/d41591-024-00024.
    PubMed    


  9. YARCHOAN M, Gane EJ, Marron TU, Perales-Linares R, et al
    Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.
    Nat Med. 2024 Apr 7. doi: 10.1038/s41591-024-02894.
    PubMed     Abstract available



  10. Systematic testing in cholera surveillance enhances vaccine impact and cost-effectiveness.
    Nat Med. 2024 Apr 3. doi: 10.1038/s41591-024-02907.
    PubMed    


    March 2024
  11. O'LEARY K
    Going the extra mile to increase vaccine uptake.
    Nat Med. 2024 Mar 28. doi: 10.1038/d41591-024-00022.
    PubMed    


  12. RAPPAPORT AR, Kyi C, Lane M, Hart MG, et al
    A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
    Nat Med. 2024 Mar 27. doi: 10.1038/s41591-024-02851.
    PubMed     Abstract available


  13. XU H, Zou K, Dent J, Wiens KE, et al
    Enhanced cholera surveillance to improve vaccination campaign efficiency.
    Nat Med. 2024 Mar 5. doi: 10.1038/s41591-024-02852.
    PubMed     Abstract available


    February 2024
  14. PERETTI-WATEL P, Verger P, Ward JK
    To understand mRNA vaccine hesitancy, stop calling the public anti-science.
    Nat Med. 2024 Feb 27. doi: 10.1038/s41591-024-02816.
    PubMed    


    January 2024
  15. O'LEARY K
    Personalized mRNA vaccine boosts melanoma immunotherapy.
    Nat Med. 2024 Jan 25. doi: 10.1038/d41591-024-00006.
    PubMed    


  16. TAYLOR TE, Osier F
    Integrating vaccines and monoclonal antibodies into malaria prevention.
    Nat Med. 2024 Jan 10. doi: 10.1038/s41591-023-02745.
    PubMed    


  17. PANT S, Wainberg ZA, Weekes CD, Furqan M, et al
    Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.
    Nat Med. 2024 Jan 9. doi: 10.1038/s41591-023-02760.
    PubMed     Abstract available


    December 2023
  18. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    Author Correction: Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial.
    Nat Med. 2023 Dec 22. doi: 10.1038/s41591-023-02772.
    PubMed    


  19. BARNABAS RV, Brown ER, Onono MA, Bukusi EA, et al
    Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results.
    Nat Med. 2023 Dec 4. doi: 10.1038/s41591-023-02658.
    PubMed     Abstract available


    November 2023
  20. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial.
    Nat Med. 2023 Nov 27. doi: 10.1038/s41591-023-02670.
    PubMed     Abstract available


  21. O'LEARY K
    A new, affordable HPV vaccine.
    Nat Med. 2023 Nov 13. doi: 10.1038/d41591-023-00095.
    PubMed    


  22. SCHOMMERS P, Kim DS, Schlotz M, Kreer C, et al
    Dynamics and durability of HIV-1 neutralization are determined by viral replication.
    Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02582.
    PubMed     Abstract available


  23. CHEHRAZI-RAFFLE A, Budde LE, Pal SK
    Boosting CAR T cells with anti-tumor mRNA vaccines.
    Nat Med. 2023 Nov 6. doi: 10.1038/s41591-023-02623.
    PubMed    


    October 2023
  24. LAU JJ, Cheng SMS, Leung K, Lee CK, et al
    Author Correction: Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.
    Nat Med. 2023 Oct 24. doi: 10.1038/s41591-023-02648.
    PubMed    


  25. MACKENSEN A, Haanen JBAG, Koenecke C, Alsdorf W, et al
    CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.
    Nat Med. 2023 Oct 23. doi: 10.1038/s41591-023-02612.
    PubMed     Abstract available


    September 2023
  26. GRASSL N, Poschke I, Lindner K, Bunse L, et al
    A H3K27M-targeted vaccine in adults with diffuse midline glioma.
    Nat Med. 2023 Sep 21. doi: 10.1038/s41591-023-02555.
    PubMed     Abstract available


    August 2023
  27. CHALKIAS S, Whatley JL, Eder F, Essink B, et al
    Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.
    Nat Med. 2023 Aug 31. doi: 10.1038/s41591-023-02517.
    PubMed     Abstract available


  28. BRANCHE AR, Rouphael NG, Diemert DJ, Falsey AR, et al
    Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.
    Nat Med. 2023 Aug 28. doi: 10.1038/s41591-023-02503.
    PubMed     Abstract available


  29. CARVALHO T
    Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial.
    Nat Med. 2023 Aug 16. doi: 10.1038/d41591-023-00072.
    PubMed    


  30. JOHNSON B
    GSK's gonorrhea vaccine receives fast-track designation to expedite clinical trials.
    Nat Med. 2023 Aug 7. doi: 10.1038/d41591-023-00069.
    PubMed    


    July 2023
  31. GUILAMO-RAMOS V, Thimm-Kaiser M, Benzekri A
    Community-engaged Mpox vaccination provides lessons for equitable health care in the United States.
    Nat Med. 2023 Jul 19. doi: 10.1038/s41591-023-02447.
    PubMed    


  32. BARNES E, Goodyear CS, Willicombe M, Gaskell C, et al
    SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
    Nat Med. 2023 Jul 6. doi: 10.1038/s41591-023-02414.
    PubMed     Abstract available


  33. BERKLEY S
    The poorest and most vulnerable communities should be the first to be vaccinated.
    Nat Med. 2023;29:1596.
    PubMed    


    June 2023

  34. Precision medicine meets cancer vaccines.
    Nat Med. 2023;29:1287.
    PubMed    


    May 2023
  35. VAN DER KLAAUW AA, Horner EC, Pereyra-Gerber P, Agrawal U, et al
    Accelerated waning of the humoral response to COVID-19 vaccines in obesity.
    Nat Med. 2023 May 11. doi: 10.1038/s41591-023-02343.
    PubMed     Abstract available


    March 2023
  36. MOORE S, Hill EM, Dyson L, Tildesley MJ, et al
    Author Correction: Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.
    Nat Med. 2023 Mar 27:1. doi: 10.1038/s41591-023-02303.
    PubMed    


  37. STAMM TA, Partheymuller J, Mosor E, Ritschl V, et al
    Determinants of COVID-19 vaccine fatigue.
    Nat Med. 2023 Mar 27. doi: 10.1038/s41591-023-02282.
    PubMed     Abstract available


  38. LIPSCHUETZ M, Guedalia J, Cohen SM, Sompolinsky Y, et al
    Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization.
    Nat Med. 2023 Mar 23. doi: 10.1038/s41591-023-02270.
    PubMed     Abstract available


  39. KHOURY DS, Docken SS, Subbarao K, Kent SJ, et al
    Predicting the efficacy of variant-modified COVID-19 vaccine boosters.
    Nat Med. 2023 Mar 2. doi: 10.1038/s41591-023-02228.
    PubMed     Abstract available


    February 2023
  40. GRANT R, Sacks JA, Abraham P, Chunsuttiwat S, et al
    When to update COVID-19 vaccine composition.
    Nat Med. 2023 Feb 20. doi: 10.1038/s41591-023-02220.
    PubMed    


  41. CARVALHO T
    mRNA vaccine effective against RSV respiratory disease.
    Nat Med. 2023 Feb 15. doi: 10.1038/d41591-023-00017.
    PubMed    


    January 2023
  42. SAGY YW, Zucker R, Hammerman A, Markovits H, et al
    Real-world effectiveness of a single dose of mpox vaccine in males.
    Nat Med. 2023 Jan 31. doi: 10.1038/s41591-023-02229.
    PubMed     Abstract available


  43. WANG G, Yao Y, Wang Y, Gong J, et al
    Determinants of COVID-19 vaccination status and hesitancy among older adults in China.
    Nat Med. 2023 Jan 31. doi: 10.1038/s41591-023-02241.
    PubMed     Abstract available


  44. O'LEARY K
    Cash rewards for vaccination.
    Nat Med. 2023 Jan 26. doi: 10.1038/d41591-023-00011.
    PubMed    


  45. LAU JJ, Cheng SMS, Leung K, Lee CK, et al
    Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.
    Nat Med. 2023 Jan 18. doi: 10.1038/s41591-023-02219.
    PubMed     Abstract available


  46. LAZARUS JV, Wyka K, White TM, Picchio CA, et al
    A survey of COVID-19 vaccine acceptance across 23 countries in 2022.
    Nat Med. 2023 Jan 9. doi: 10.1038/s41591-022-02185.
    PubMed     Abstract available


  47. OGONGO P, Ernst JD
    Finding antigens for TB vaccines: the good, the bad and the useless.
    Nat Med. 2023 Jan 5. doi: 10.1038/s41591-022-02123.
    PubMed    


    December 2022
  48. KURHADE C, Zou J, Xia H, Liu M, et al
    Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster.
    Nat Med. 2022 Dec 6. doi: 10.1038/s41591-022-02162.
    PubMed     Abstract available


  49. O'LEARY K
    The next generation of COVID-19 vaccines.
    Nat Med. 2022;28:2450.
    PubMed    


    November 2022
  50. O'LEARY K
    A universal flu vaccine on the horizon.
    Nat Med. 2022 Nov 30. doi: 10.1038/d41591-022-00113.
    PubMed    



  51. Quantifying the effect of inequitable global vaccine coverage on the COVID-19 pandemic.
    Nat Med. 2022 Nov 4. pii: 10.1038/s41591-022-02065.
    PubMed    


  52. CARVALHO T
    Intranasal COVID-19 vaccine fails to induce mucosal immunity.
    Nat Med. 2022 Nov 3. pii: 10.1038/d41591-022-00106.
    PubMed    


    October 2022
  53. MOORE S, Hill EM, Dyson L, Tildesley MJ, et al
    Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.
    Nat Med. 2022 Oct 27. pii: 10.1038/s41591-022-02064.
    PubMed     Abstract available


  54. BAILON L, Llano A, Cedeno S, Escriba T, et al
    Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
    Nat Med. 2022 Oct 27. pii: 10.1038/s41591-022-02060.
    PubMed     Abstract available


  55. SCHEAFFER SM, Lee D, Whitener B, Ying B, et al
    Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Nat Med. 2022 Oct 20. pii: 10.1038/s41591-022-02092.
    PubMed     Abstract available


  56. ZAECK LM, Lamers MM, Verstrepen BE, Bestebroer TM, et al
    Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals.
    Nat Med. 2022 Oct 18. pii: 10.1038/s41591-022-02090.
    PubMed     Abstract available


  57. MENTZER AJ, O'Connor D, Bibi S, Chelysheva I, et al
    Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
    Nat Med. 2022 Oct 13. pii: 10.1038/s41591-022-02078.
    PubMed     Abstract available


  58. BHATTACHARYA D, Victora GD
    Boosting with updated COVID-19 mRNA vaccines.
    Nat Med. 2022 Oct 6. pii: 10.1038/s41591-022-02048.
    PubMed    


  59. CHALKIAS S, Eder F, Essink B, Khetan S, et al
    Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
    Nat Med. 2022 Oct 6. pii: 10.1038/s41591-022-02031.
    PubMed     Abstract available


    September 2022
  60. CARVALHO T
    mRNA vaccines boost BioNTech's CAR T cell therapy.
    Nat Med. 2022 Sep 1. pii: 10.1038/d41591-022-00091.
    PubMed    


    August 2022
  61. PALMER CD, Rappaport AR, Davis MJ, Hart MG, et al
    Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.
    Nat Med. 2022;28:1619-1629.
    PubMed     Abstract available


    July 2022
  62. LUONG NGUYEN LB, Ghosn J, Durier C, Tachot C, et al
    A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox.
    Nat Med. 2022 Jul 13. pii: 10.1038/d41591-022-00077.
    PubMed    


  63. JARA A, Undurraga EA, Zubizarreta JR, Gonzalez C, et al
    Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile.
    Nat Med. 2022;28:1377-1380.
    PubMed     Abstract available


    June 2022
  64. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    A randomized controlled trial to test financial incentives for COVID-19 vaccination in Ghana.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01876.
    PubMed    


  65. CAO L, Lou J, Chan SY, Zheng H, et al
    Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01877.
    PubMed     Abstract available


    May 2022
  66. O'LEARY K
    Finding a vaccine for Epstein-Barr virus.
    Nat Med. 2022 May 19. pii: 10.1038/d41591-022-00061.
    PubMed    


  67. MOLINO D, Durier C, Radenne A, Desaint C, et al
    A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project.
    Nat Med. 2022 May 5. pii: 10.1038/s41591-022-01785.
    PubMed    


  68. CHU L, Vrbicky K, Montefiori D, Huang W, et al
    Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
    Nat Med. 2022;28:1042-1049.
    PubMed     Abstract available


  69. TSENG HF, Ackerson BK, Luo Y, Sy LS, et al
    Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.
    Nat Med. 2022;28:1063-1071.
    PubMed     Abstract available


    April 2022
  70. O'LEARY K
    Single vaccine shot protects against cervical cancer.
    Nat Med. 2022 Apr 25. pii: 10.1038/d41591-022-00056.
    PubMed    


  71. ARBEL R, Sergienko R, Friger M, Peretz A, et al
    Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years.
    Nat Med. 2022 Apr 25. pii: 10.1038/s41591-022-01832.
    PubMed     Abstract available


  72. PUHACH O, Adea K, Hulo N, Sattonnet P, et al
    Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.
    Nat Med. 2022 Apr 8. pii: 10.1038/s41591-022-01816.
    PubMed     Abstract available


  73. PAJON R, Paila YD, Girard B, Dixon G, et al
    Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial.
    Nat Med. 2022;28:823-830.
    PubMed     Abstract available


    March 2022
  74. WEBSTER P
    Russian COVID-19 vaccine in jeopardy after Ukraine invasion.
    Nat Med. 2022 Mar 15. pii: 10.1038/d41591-022-00042.
    PubMed    


  75. PERTWEE E, Simas C, Larson HJ
    An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy.
    Nat Med. 2022 Mar 10. pii: 10.1038/s41591-022-01728.
    PubMed     Abstract available


  76. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2022 Mar 8. pii: 10.1038/s41591-022-01771.
    PubMed    


  77. GRUELL H, Vanshylla K, Tober-Lau P, Hillus D, et al
    mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.
    Nat Med. 2022;28:477-480.
    PubMed     Abstract available


  78. GAO Y, Cai C, Grifoni A, Muller TR, et al
    Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.
    Nat Med. 2022;28:472-476.
    PubMed     Abstract available


    February 2022
  79. DU Z, Wang L, Pandey A, Lim WW, et al
    Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India.
    Nat Med. 2022 Feb 24. pii: 10.1038/s41591-022-01736.
    PubMed     Abstract available


  80. AULADELL M, Phuong HVM, Mai LTQ, Tseng YY, et al
    Influenza virus infection history shapes antibody responses to influenza vaccination.
    Nat Med. 2022 Feb 17. pii: 10.1038/s41591-022-01690.
    PubMed     Abstract available


  81. VALKENBURG SA, Poon LLM
    Exploring the landscape of immune responses to influenza infection and vaccination.
    Nat Med. 2022 Feb 17. pii: 10.1038/s41591-021-01656.
    PubMed    


  82. WEI J, Pouwels KB, Stoesser N, Matthews PC, et al
    Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
    Nat Med. 2022 Feb 14. pii: 10.1038/s41591-022-01721.
    PubMed     Abstract available


  83. CERQUEIRA-SILVA T, Katikireddi SV, de Araujo Oliveira V, Flores-Ortiz R, et al
    Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.
    Nat Med. 2022 Feb 9. pii: 10.1038/s41591-022-01701.
    PubMed     Abstract available


  84. STOCK SJ, Carruthers J, Calvert C, Denny C, et al
    Author Correction: SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.
    Nat Med. 2022 Feb 4. pii: 10.1038/s41591-022-01730.
    PubMed    


  85. ANDREWS SF, Raab JE, Gorman J, Gillespie RA, et al
    A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01636.
    PubMed     Abstract available


  86. HOUSER KV, Chen GL, Carter C, Crank MC, et al
    Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01660.
    PubMed     Abstract available


    January 2022
  87. WRATIL PR, Stern M, Priller A, Willmann A, et al
    Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
    Nat Med. 2022 Jan 28. pii: 10.1038/s41591-022-01715.
    PubMed     Abstract available


  88. LI J, Hou L, Guo X, Jin P, et al
    Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
    Nat Med. 2022 Jan 27. pii: 10.1038/s41591-021-01677.
    PubMed     Abstract available


  89. PEREZ-THEN E, Lucas C, Monteiro VS, Miric M, et al
    Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
    Nat Med. 2022 Jan 20. pii: 10.1038/s41591-022-01705.
    PubMed     Abstract available


  90. CHENG SMS, Mok CKP, Leung YWY, Ng SS, et al
    Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination.
    Nat Med. 2022 Jan 20. pii: 10.1038/s41591-022-01704.
    PubMed     Abstract available


  91. ANDREWS N, Stowe J, Kirsebom F, Toffa S, et al
    Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England.
    Nat Med. 2022 Jan 14. pii: 10.1038/s41591-022-01699.
    PubMed     Abstract available


  92. STOCK SJ, Carruthers J, Calvert C, Denny C, et al
    SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.
    Nat Med. 2022 Jan 13. pii: 10.1038/s41591-021-01666.
    PubMed     Abstract available


  93. WARD JK, Gauna F, Gagneux-Brunon A, Botelho-Nevers E, et al
    The French health pass holds lessons for mandatory COVID-19 vaccination.
    Nat Med. 2022 Jan 12. pii: 10.1038/s41591-021-01661.
    PubMed    


  94. ETIENNE CF
    COVID-19 has revealed a pandemic of inequality.
    Nat Med. 2022;28:17.
    PubMed    


    December 2021
  95. PATONE M, Mei XW, Handunnetthi L, Dixon S, et al
    Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
    Nat Med. 2021 Dec 14. pii: 10.1038/s41591-021-01630.
    PubMed     Abstract available


  96. ADEPOJU P
    As COVID-19 vaccines arrive in Africa, Omicron is reducing supply and increasing demand.
    Nat Med. 2021 Dec 13. pii: 10.1038/d41591-021-00073.
    PubMed    



  97. Vaccine development needs a boost.
    Nat Med. 2021 Dec 2. pii: 10.1038/s41591-021-01633.
    PubMed    


  98. O'LEARY K
    A malaria vaccine at last.
    Nat Med. 2021;27:2057.
    PubMed    


  99. MORRIS L
    mRNA vaccines offer hope for HIV.
    Nat Med. 2021;27:2082-2084.
    PubMed    


  100. ZHANG P, Narayanan E, Liu Q, Tsybovsky Y, et al
    A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.
    Nat Med. 2021;27:2234-2245.
    PubMed     Abstract available


  101. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2021;27:2212-2223.
    PubMed     Abstract available


  102. VAN KERKHOVE MD
    COVID-19 in 2022: controlling the pandemic is within our grasp.
    Nat Med. 2021;27:2070.
    PubMed    


  103. WEBSTER P
    COVID-19 timeline of events.
    Nat Med. 2021;27:2054-2055.
    PubMed    


  104. MAY M
    Eight unanswered questions about the COVID-19 pandemic.
    Nat Med. 2021;27:2058-2061.
    PubMed    


  105. ARNOLD C
    11 clinical trials that will shape medicine in 2022.
    Nat Med. 2021;27:2062-2064.
    PubMed    


    November 2021
  106. PATONE M, Handunnetthi L, Saatci D, Pan J, et al
    Publisher Correction: Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
    Nat Med. 2021 Nov 29. pii: 10.1038/s41591-021-01644.
    PubMed    


  107. O'LEARY K
    An mRNA vaccine against tick bites.
    Nat Med. 2021 Nov 25. pii: 10.1038/d41591-021-00071.
    PubMed    


  108. JUNO JA, Wheatley AK
    Boosting immunity to COVID-19 vaccines.
    Nat Med. 2021 Nov 11. pii: 10.1038/s41591-021-01560.
    PubMed    


  109. O'LEARY K
    HPV vaccines beat cervical cancer.
    Nat Med. 2021 Nov 11. pii: 10.1038/d41591-021-00068.
    PubMed    


  110. TANG P, Hasan MR, Chemaitelly H, Yassine HM, et al
    BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01583.
    PubMed     Abstract available


  111. LEVINE-TIEFENBRUN M, Yelin I, Alapi H, Katz R, et al
    Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01575.
    PubMed     Abstract available


  112. FENG S, Phillips DJ, White T, Sayal H, et al
    Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
    Nat Med. 2021;27:2032-2040.
    PubMed     Abstract available


    October 2021
  113. PATONE M, Handunnetthi L, Saatci D, Pan J, et al
    Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
    Nat Med. 2021 Oct 25. pii: 10.1038/s41591-021-01556.
    PubMed     Abstract available


  114. POUWELS KB, Pritchard E, Matthews PC, Stoesser N, et al
    Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.
    Nat Med. 2021 Oct 14. pii: 10.1038/s41591-021-01548.
    PubMed     Abstract available


  115. ALI M, Khan J, Ahmad N, Khan H, et al
    COVID-19 vaccination gives hope to eradicate polio.
    Nat Med. 2021 Oct 4. pii: 10.1038/s41591-021-01518.
    PubMed    


    September 2021
  116. O'LEARY K
    Low-dose mRNA vaccination measures up.
    Nat Med. 2021 Sep 30. pii: 10.1038/d41591-021-00060.
    PubMed    


  117. SHROFF RT, Chalasani P, Wei R, Pennington D, et al
    Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.
    Nat Med. 2021 Sep 30. pii: 10.1038/s41591-021-01542.
    PubMed     Abstract available


  118. CHOOKAJORN T, Kochakarn T, Wilasang C, Kotanan N, et al
    Southeast Asia is an emerging hotspot for COVID-19.
    Nat Med. 2021;27:1495-1496.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.